Bulletin du cancer
-
Scientific knowledge on gastrointestinal stromal tumors (GIST) has highly progressed over the last 10 years. The molecular bases of oncogenic transformation, KIT activating mutations, were identified in 1998 by Hirota et al. The product of KIT proto-oncogene, KIT protein, is a transmembrane receptor with tyrosine kinase activity. ⋯ Molecular biology in GIST is now becoming a routine tool for treatment selection. In patients with advanced GIST, imatinib should be given until progression, and then, other tyrosine kinase inhibitors targeting KIT should be used. In the adjuvant setting, the optimal duration of imatinib treatment remains unknown.
-
Resulting medical decision from a multidisciplinary team (MDT) meeting has to be accurate regarding to various patient criteria and relevant specialists participation. The target is to optimize treatment or management options for patients taking into account patients' benefit. The aim of our study was to examine quality criteria of MDT meeting processes, implementation of the MDT decision, and the follow-up of national or regional clinical guidelines. ⋯ Participation in MDT meetings is more and more time-consuming related to enforce the completeness referred to the Plan Cancer (National recommendations). Leading to completeness raises questions about medical time employment and meaning of the MDT meeting for standard clinical cases. The priority seems to enforce multidisciplinarity rather than reach completeness.
-
As part of a quality assurance program, we assessed the trend of our analgesic consumption using our anesthesia database which include anesthesia and postanesthetic care records for all patients. In recent years, emphasis was made on anesthesia personnel to decrease postoperative opioid analgesic at the expense of non-opioid analgesics in order to decrease opioid related side effects. The following items were recorded: intraoperative opioid consumption, total morphine consumption, non-opioid analgesic consumption pain and sedation scores in the postoperative care unit (PACU). ⋯ Total morphine consumption per patient in the operative room and in the PACU decreased significantly from 11 ± 4 mg in year 2002 to 7 ± 3 mg in 2010, P < 0.05. In the intraoperative period, remifentanil/sufentanil ratio increased significantly from 33/67 to 87/13% of patients (P < 0.05) without affecting pain scores in the PACU. This multi-year trend shows a significant decrease in overall postoperative morphine consumption, in addition we showed that computerized database can easily follow the trend of analgesic consumption and can be used therefore as a powerful tool with easy access as part of a quality assurance program.
-
Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches. In Philadelphia chromosome-positive (Ph(+)) ALL, the optimal treatment requires the addition of BCR-ABL tyrosine kinase inhibitors, as imatinib. However, the outcome remains poor in absence of allogeneic stem cell transplantation, and novel agents are desperately required. ⋯ Despite these therapeutic options, the cross-resistant BCR-ABL (T315I) mutation remains a major clinical challenge. The first evaluations of AP24534 present this drug as a potent multi-targeted kinase inhibitor active against T315I and all other BCR-ABL mutants. AP24534 could be the next treatment of choice in hematological malignancies with Philadelphia-positive chromosome, particularly Ph(+) ALL known for its frequent occurrence of T315I mutation.
-
Brain metastases are prevalent in solid tumours and lymphomas. They are associated with poor survival. ⋯ Specific strategies are needed to fight brain metastatic disease. Preclinical models for brain metastasis have been developed, yielding mechanistic molecular knowledge and new therapeutic approaches.